1063665--9/23/2010--CORGENIX_MEDICAL

related topics

{product, candidate, development}

{acquisition, growth, future}

{product, liability, claim}

{customer, product, revenue}

{operation, international, foreign}

{stock, price, share}

{personnel, key, retain}

{property, intellectual, protect}

{product, market, service}

{regulation, government, change}

We depend upon collaborative relationships and third parties for product development and commercialization. There can be no assurance of successful or timely development of additional products. We continue to incur losses and require additional financing. Competition in the human medical diagnostics industry is, and is expected to remain, significant. Our products and activities are subject to regulation by various governments and government agencies. We depend upon distribution partners for sales of diagnostic products in international markets. Third party reimbursement for purchases of our diagnostic products is uncertain. Our success depends, in part, on our ability to obtain patents and license patent rights, to maintain trade secret protection and to operate without infringing on the proprietary rights of others. We may not be able to successfully implement our plans to acquire other companies or technologies. We depend on suppliers for our products' components. We have only limited manufacturing experience with certain products. Due to the specialized nature of our business, our success will be highly dependent upon our ability to attract and retain qualified scientific and executive personnel. The testing, manufacturing and marketing of medical diagnostic devices entails an inherent risk of product liability claims. There has, to date, been no consistently active public market for our common stock, and there can be no assurance that a consistently active public market will develop or be sustained. There are risks associated with fluctuating exchange rates.

Full 10-K form ▸

1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO